Accelerating the development of targeted neuromodulation therapies
The National Institutes of Health invited four Phase 2 winners to conduct IDE-enabling studies in Phase 3.
Congratulations to the Phase 3 cohort
Anthony F. DiMarco, M.D.
High-frequency spinal cord stimulation reduces respiratory tract infections and improves bowel management in people with neurological impairment.
Juniper Biomedical (formerly RBI Medical)
Highly precise, micro-implantable neuromodulation to treat stress urinary incontinence, overactive bladder and fecal incontinence.
University of Louisville Research Foundation Inc.
StimXS, neuromodulation of the lumbosacral spinal cord, automatically regulates cardiovascular, respiratory, and urinary systems after spinal cord injury.
University of Pittsburgh Department of Urology
A novel multi-channel implantable device for sacral-pudendal neuromodulation to treat bladder, bowel, and sexual disorders.
About the competition
The Neuromod Prize is a SPARC (Stimulating Peripheral Activity to Relieve Conditions) initiative from the National Institutes of Health (NIH) Common Fund. The competition seeks groundbreaking uses of peripheral nerve stimulation that can independently regulate two or more desired autonomic functions without unintended effects on non-target organs. The competition is currently in Phase 3.
CONCLUDED
Phase 1
Open to all eligible participants
Participants submitted concept papers describing their proposed therapeutic approach and plans for conducting proof-of-concept studies.
CONCLUDED
Phase 2
Open to winners of Phase 1
Eight Phase 1 winners were exclusively invited to develop proof-of-concept studies.
CURRENT
Phase 3
Open to winners of Phase 2
Four Phase 2 winners were exclusively invited to conduct IDE-enabling studies.
Prize pool
A judging panel selected eight winners according to official Phase 1 judging criteria. Phase 1 winners each received $100,000 and the opportunity to compete for a share of $4 million in Phase 2. Four Phase 2 winners were selected to receive $1 million each and were invited to advance to Phase 3, where they have the opportunity to compete for a share of $5 million.
Total prize pool across three phases
Timeline
Phase 1 was open to all eligible participants — including scientists, engineers, and clinicians — to submit novel concepts and plans for development. Phase 2 invited eight Phase 1 winners to build on their submissions. The competition is currently in Phase 3, where four winners from Phase 2 are conducting IDE-enabling studies.
Phase 1 launch
Phase 1 submission deadline
Phase 1 winner announcement
Phase 2 launch
Phase 2 winner announcement
Phase 3 launch
Phase 3 winner announcement